International Biotechnology Trust PLC Has $621,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
International Biotechnology Trust PLC Has $621,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
International Biotechnology Trust PLC boosted its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 8,570.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,000 shares of the biotechnology company's stock after purchasing an additional 59,308 shares during the period. International Biotechnology Trust PLC's holdings in Ironwood Pharmaceuticals were worth $621,000 as of its most recent filing with the SEC.
国际生物技术信托公司(International Biotech Trust PLC)最近提交给美国证券交易委员会(Form 13F，简称：美国证券交易委员会)的文件显示，该公司第三季度增持铁木制药股份有限公司(Form 13F)股份，增持幅度达8,570.5%。在此期间，该基金又购买了59,308股生物技术公司的股票，目前持有60,000股。截至国际生物技术信托公司最近向美国证券交易委员会提交的文件，该公司持有的铁木制药股份价值62.1万美元。
A number of other hedge funds also recently made changes to their positions in the business. KBC Group NV acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at approximately $129,000. LSV Asset Management lifted its position in shares of Ironwood Pharmaceuticals by 5.8% in the third quarter. LSV Asset Management now owns 7,914,220 shares of the biotechnology company's stock valued at $81,991,000 after buying an additional 435,063 shares during the last quarter. Inspire Investing LLC lifted its position in shares of Ironwood Pharmaceuticals by 14.7% in the third quarter. Inspire Investing LLC now owns 20,981 shares of the biotechnology company's stock valued at $217,000 after buying an additional 2,690 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at approximately $153,000. Finally, Creative Planning lifted its position in shares of Ironwood Pharmaceuticals by 10.3% in the third quarter. Creative Planning now owns 29,184 shares of the biotechnology company's stock valued at $302,000 after buying an additional 2,726 shares during the last quarter.
其他一些对冲基金最近也调整了它们在该业务中的头寸。KBC Group NV在第三季度收购了Ironwood PharmPharmticals的新股份，价值约12.9万美元。LSV资产管理公司在第三季度将其在Ironwood PharmPharmticals股票的头寸提高了5.8%。LSV资产管理公司现在拥有这家生物技术公司7914,220股票，价值81,991,000美元，在上个季度又购买了435,063股票。Inspire Investment LLC在第三季度将其在Ironwood PharmPharmticals股票的头寸提高了14.7%。Inspire Investment LLC现在持有这家生物技术公司20,981股股票，价值21.7万美元，在上个季度又购买了2,690股。Jump Financial LLC在第三季度收购了铁木制药公司的新股份，价值约15.3万美元。最后，创意策划在第三季度将其在Ironwood PharmPharmticals的股票头寸提高了10.3%。在上个季度又购买了2,726股后，Creative Planning现在拥有29,184股这家生物技术公司的股票，价值30.2万美元。
Insider Transactions at Ironwood Pharmaceuticals
铁木制药的内幕交易
In other news, CEO Thomas A. Mccourt sold 110,962 shares of the stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the transaction, the chief executive officer now owns 712,440 shares in the company, valued at $8,599,150.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 13.10% of the stock is owned by corporate insiders.
在其他消息方面，首席执行官托马斯·A·麦考特在1月5日星期四的一笔交易中出售了110,962股该公司股票。该股以12.07美元的平均价格出售，总成交金额为1,339,311.34美元。交易完成后，这位首席执行官现在拥有该公司712,440股票，价值8,599,150.80美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。13.10%的股份由企业内部人士持有。
Ironwood Pharmaceuticals Stock Performance
铁木制药的股票表现
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last announced its earnings results on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. The company had revenue of $108.64 million for the quarter, compared to analyst estimates of $111.51 million. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%. Sell-side analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.99 EPS for the current year.
铁木制药(纳斯达克代码：IRWD-GET Rating)最近一次公布财报是在11月3日星期四。这家生物技术公司公布本季度每股收益为0.28美元，比分析师普遍预期的0.27美元高出0.01美元。该公司本季度营收为1.0864亿美元，而分析师预期为1.1151亿美元。Ironwood PharmPharmticals的股本回报率为30.24%，净利润率为39.85%。卖方分析师预测，Ironwood PharmPharmticals，Inc.本年度每股收益将达到0.99美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, StockNews.com cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 17th.
另外，StockNews.com在12月17日(星期六)的一份研究报告中将Ironwood PharmPharmticals的评级从“强力买入”下调至“买入”。
About Ironwood Pharmaceuticals
铁木制药公司简介
(Get Rating)
(获取评级)
Ironwood Pharmaceuticals, Inc is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation.
Ironwood PharmPharmticals，Inc.是一家医疗保健公司，专注于在重大未得到满足的需求领域开发和商业化胃肠(GI)产品机会，利用已证明的胃肠道疾病方面的专业知识和能力。它的产品包括利纳氯肽，一种鸟苷环化酶C型激动剂，用于治疗患有便秘和慢性便秘的肠易激综合征患者。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- Old Dominion Freight Line Driving To New Highs
- AMD Results Are No Reason To Buy Semiconductors... Yet
- Institutions are Buying up Procter & Gamble Shares, Should you?
- How Do Lawsuits Affect Johnson & Johnson's Stock Price?
- Has The Salesforce Turnaround Begun?
- 免费获取StockNews.com关于铁木制药的研究报告(IRWD)
- 老Dominion货运线再创新高
- AMD的结果不是购买半导体的理由。还没有
- 机构正在买进宝洁的股票，你应该这样做吗？
- 诉讼对强生的股价有何影响？
- Salesforce的扭亏为盈开始了吗？
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ironwood PharmPharmticals Daily新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ironwood PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。